Alberto López-De la Rosa

Alberto López-De la Rosa

Auto-generated profile, based on publicly available information

Alberto López-De la Rosa

Department of Theoretical Physics, Atomic and Optics University of Valladolid Valladolid Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Ocular Surface
Verified
Journal Article
Closed access
Jose Pinto-FragaJose Pinto-Fraga
Jose Pinto-Fraga
Amalia Enríquez-de-SalamancaAmalia Enríquez-de-Salamanca
Amalia Enríquez-de-Salamanca
MCMargarita Calonge
Margarita Calonge
MGMaría J. González-García
María J. González-García
AMAlberto López Miguel
Alberto López Miguel
IMItziar Fernández Martínez
Itziar Fernández Martínez

1 January 2016 in Ophthalmology
Verified
Journal Article
Closed access
Jose Pinto-FragaJose Pinto-Fraga
Jose Pinto-Fraga
AMAlberto López Miguel
Alberto López Miguel
MGMaría J. González-García
María J. González-García
IMItziar Fernández Martínez
Itziar Fernández Martínez
ALAlberto López-De-La-Rosa
Alberto López-De-La-Rosa
MCMargarita Calonge
Margarita Calonge

1 January 2017 in Eye & Contact Lens: Science & Clinical Practice
Verified
Journal Article
Closed access
Jose Pinto-FragaJose Pinto-Fraga
Jose Pinto-Fraga
ARAlberto López-De la Rosa
Alberto López-De la Rosa
FAFrancisco Blázquez Arauzo
Francisco Blázquez Arauzo
RRRubén Urbano Rodríguez
Rubén Urbano Rodríguez
MGMaría J. González-García
María J. González-García
Objectives: To evaluate the safety and efficacy of a new artificial tear containing 0.2% hyaluronic acid, as compared with 0.9% saline solution, in mild dry eye patients after 1-month use in a crossover study design with washout periods. Methods: Overall, 16 mild dry eye patients were included. After a week of washout, every patient used the experimental product (Visaid 0.2%) and the control product (0.9% saline solution), each for a month (3–8 drops daily). Both products were preservative free. The percentage change for the following variables were calculated and analyzed: Ocular Surface Disease Index (OSDI) questionnaire, visual acuity, intraocular pressure, ophthalmoscopy evaluation, biomicroscopy findings, fluorescein corneal staining and lissamine green conjunctival staining, tear breakup time, contrast sensitivity, Schirmer's test, and subject satisfaction. Results: Patients reported an improvement (a significant decrease of −19.5%±27.5%) in OSDI scores after using Visaid 0.2% and a worsening (a significant increase of 19.2%±32.4%) after using 0.9% saline solution; the difference was significant (P=0.0087, Student's t test). Significant changes (P≤0.04, Wilcoxon's test) were found comparing Visaid 0.2% with saline solution for bulbar hyperemia (−39.1%±50.8% vs. 7.8%±12.0%, respectively), corneal staining (−26.0%±53.0% vs. 36.5%±73.3%), conjunctival staining (−54.7%±53.4% vs. −7.8%±47.2%), and subjective satisfaction (26.8%±28.5% vs. −13.3%±22.5%). There were no significant differences in the safety parameters for either solution. Conclusion: This clinical trial demonstrates the safety of Visaid 0.2% and its clear benefit over 0.9% saline solution.

1 January 2017 in International Ophthalmology Clinics
Verified
Journal Article
Closed access
PDF file
MCMargarita Calonge
Margarita Calonge
Jose Pinto-FragaJose Pinto-Fraga
Jose Pinto-Fraga
MGMaría J. González-García
María J. González-García
Amalia Enríquez-de-SalamancaAmalia Enríquez-de-Salamanca
Amalia Enríquez-de-Salamanca
ARAlberto López-De la Rosa
Alberto López-De la Rosa
AMAlberto López Miguel
Alberto López Miguel

1 August 2016 in Optometry and Vision Science
Verified
Journal Article
Closed access
ARAlberto López–De la Rosa
Alberto López–De la Rosa
VMVicente Martín‐Montañez
Vicente Martín‐Montañez
AMAlberto López Miguel
Alberto López Miguel
MCMargarita Calonge
Margarita Calonge
Amalia Enríquez-de-SalamancaAmalia Enríquez-de-Salamanca
Amalia Enríquez-de-Salamanca
MGMaría J. González-García
María J. González-García

1 June 2021 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
EMElena Martínez-Plaza
Elena Martínez-Plaza
AMAlberto López Miguel
Alberto López Miguel
ARAlberto López-De la Rosa
Alberto López-De la Rosa
Colm McAlindenColm McAlinden
Colm McAlinden
IMItziar Fernández Martínez
Itziar Fernández Martínez
MMMiguel J. Maldonado
Miguel J. Maldonado